Hyperway Pharmaceuticals secures ¥200M+ Series B+ to advance clinical-stage pipelines
Recently, Chengdu Hyperway Pharmaceuticals ("Hyperway"), a new biopharmaceutical company focusing on the research and development of small molecule targeted innovative drugs, announced the successful completion of a Series B financing round of more than RMB 200 million. This round of financing was led by Huagai Capital, with follow-on investments from institutions such as Genesis Capital, Tao Capital, and Panlin Capital. Existing shareholder Xincheng Fund continued to invest additional capital. Haoyue Capital acted as the exclusive financial advisor for this round of financing.
Hyperway Pharmaceuticals was established in 2019 and is headquartered in Chengdu. As a high-growth high-tech enterprise, the company is clinically demand-oriented and driven by pioneering innovation, focusing on the development of targeted innovative drugs. It has assembled an international and professional R&D management team that covers all specialized areas across the entire chain of innovative drug development—from target screening to registration and market approval. The company demonstrates rapid R&D progress and delivers high-quality outcomes, having established over ten distinctive innovative drug pipelines. These efforts concentrate on several high-demand fields such as oncology, pain management, and central nervous system diseases, and the company has built a differentiated drug delivery platform targeting brain permeability.
The company's independently developed novel analgesic Nav1.8 inhibitor, HBW-004285 tablets, is leading in domestic progress. Multiple Phase II clinical studies for postoperative acute pain are currently underway, with all patient enrollment expected to be completed by the end of 2025. Additionally, an application for Phase II clinical trials with the U.S. FDA has been initiated.
The fourth-generation BTK inhibitor HBW-3220 addresses the frequent drug resistance issues associated with earlier generations of BTK inhibitors and has demonstrated impressive clinical data. For CLL/SLL patients previously treated with irreversible BTK inhibitors and BCL2 inhibitors, the objective response rate (ORR) surpasses that of Pirtobrutinib.
Furthermore, the company has strategically expanded into the KRAS inhibitor field, with two oral innovative drugs achieving significant progress:
The KRAS G12D inhibitor HBW-012336 has overcome the international challenge of low oral exposure and is currently in Phase I clinical studies.
The Pan-KRAS inhibitor HBW-012462, capable of inhibiting both KRAS (ON) and KRAS (OFF) states, submitted an IND application in August this year.
Both innovative drugs have demonstrated high potency, high selectivity, high tissue targeting, and potent tumor suppression in preclinical studies.
The funds raised in this round will be primarily used to advance Hyperway Pharmaceuticals' core pipeline clinical studies and several preclinical pipelines, accelerating the process of bringing the company's innovative drugs to the clinic, commercialization, and international markets. With the support of this round of capital, it is believed that Hyperway Pharmaceuticals will continue to expand its strategic layout and ultimately benefit a broad patient population at an earlier date.